Home | Medical-Newswire.Com:
(Medical-NewsWire.com, October 12, 2017 ) According to Publisher, the Veterinary Anti-infectives market is accounted for $4.79 billion in 2015 and is expected to reach $9.11 billion by 2022 growing at a CAGR of 9.6% from 2015 to 2022. Growing zoonotic and foodborne diseases and greater livestock production are the key factors fueling the market growth. Increased competition for cultivated land and cost effective production are the major factors that are hampering the market growth. On the other hand, with constant innovation and quick technological advancements, the probability of decreasing the cost of anti-infective drugs is high.
For more information http://www.reportsweb.com/veterinary-antiinfectives-global-market-outlook-2015-2022
Some of the key players in the market include Novartis Animal Health, Inc., Virbac, Boehringer Ingelheim, Zoetis, Ceva Animal Health, Bayer healthcare, Heska Corporation, Merial Animal Health, Bioniche Animal Health Canada, Inc., Merck & Co., Inc.,Sanofi-Aventis, Pfizer Inc. and Elanco.
Request Sample Copy http://www.reportsweb.com/inquiry&RW0001322780/sample
-Rest of Europe
-Rest of Asia Pacific
-Rest of the World
9 Company Profiling
9.1 Novartis Animal Health, Inc.
9.3 Boehringer Ingelheim
9.5 Ceva Animal Health
9.6 Bayer healthcare
9.7 Heska Corporation
9.8 Merial Animal Health
9.9 Bioniche Animal Health Canada, Inc.
9.10 Merck & Co., Inc.,
9.12 Pfizer Inc.
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001322780/buying